Physician profile
Travis A Holt
NPI 1932320819
$2,116.33
in general payments reported to CMS, 2019-2025
14 companies · $80.45 in 2025
The $80.45 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,367 · 2020: $107 · 2021: $288 · 2023: $178 · 2024: $96.83 · 2025: $80.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $233 · Gift: $81.81 · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.34 |
| Gift | $81.81 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,296.22 | 2019 | |
| Braintree Laboratories, INC. | $343.83 | 2020-2023 | Sutab |
| Smith+Nephew, INC. | $145.88 | 2024-2025 | Stravix Pl, Grafix Pl |
| Ethicon US, LLC | $114.72 | 2019-2024 | Echelon Flex, Echelon Endopath, Dermabond |
| Heron Therapeutics, INC. | $32.65 | 2021 | |
| Coopersurgical, INC. | $31.84 | 2021 | |
| Organogenesis INC. | $30.04 | 2023 | Puraply |
| Baudax Bio INC. | $22.03 | 2021 | |
| Integra Lifesciences Corporation | $19.91 | 2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Myriad Genetic Laboratories, INC. | $18.43 | 2023 | Myrisk |
| Convatec INC. | $17.62 | 2021 | |
| Merck Sharp & Dohme LLC | $16.86 | 2019 | |
| Biocomposites INC | $13.27 | 2025 | Stimulan |
| Abbvie INC. | $13.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.